BioStock: Promore Pharma strengthens IP-protection

On Wednesday, Solna-based Promore Pharma could kick off the autumn news flow with good patent news. The company has been granted a patent in Europe for the candidate ropocamptide, which is being developed for the treatment of venous leg ulcers. BioStock contacted CEO Jonas Ekblom for a brief comment on the importance of the approval and the company’s strategy for IP protection.

Read the article at biostock.se:

https://www.biostock.se/en/2022/08/promore-pharma-strengthens-ip-protection/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/